HomeCompareIDRSF vs MCD

IDRSF vs MCD: Dividend Comparison 2026

IDRSF yields 48.90% · MCD yields 2.34%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 IDRSF wins by $294.4K in total portfolio value
10 years
IDRSF
IDRSF
● Live price
48.90%
Share price
$4.09
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$372.2K
Annual income
$74,100.38
Full IDRSF calculator →
MCD
McDonald's Corporation
● Live price
2.34%
Share price
$310.79
Annual div
$7.26
5Y div CAGR
42.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$77.7K
Annual income
$25,833.37
Full MCD calculator →

Portfolio growth — IDRSF vs MCD

📍 IDRSF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodIDRSFMCD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, IDRSF + MCD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
IDRSF pays
MCD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

IDRSF
Annual income on $10K today (after 15% tax)
$4,156.48/yr
After 10yr DRIP, annual income (after tax)
$62,985.32/yr
MCD
Annual income on $10K today (after 15% tax)
$198.56/yr
After 10yr DRIP, annual income (after tax)
$21,958.36/yr
At 15% tax rate, IDRSF beats the other by $41,026.96/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of IDRSF + MCD for your $10,000?

IDRSF: 50%MCD: 50%
100% MCD50/50100% IDRSF
Portfolio after 10yr
$225.0K
Annual income
$49,966.88/yr
Blended yield
22.21%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MCD right now

IDRSF
Analyst Ratings
1
Buy
1
Hold
Consensus: Buy
Altman Z
-10.1
Piotroski
3/9
MCD
Analyst Ratings
37
Buy
23
Hold
1
Sell
Consensus: Buy
Price Target
$351.76
+13.2% upside vs current
Range: $320.00 — $385.00
Altman Z
4.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

IDRSF buys
0
MCD buys
0
No recent congressional trades found for IDRSF or MCD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricIDRSFMCD
Forward yield48.90%2.34%
Annual dividend / share$2.00$7.26
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%42.3%
Portfolio after 10y$372.2K$77.7K
Annual income after 10y$74,100.38$25,833.37
Total dividends collected$295.4K$57.7K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary
Analyst consensusBuyBuy

Year-by-year: IDRSF vs MCD ($10,000, DRIP)

YearIDRSF PortfolioIDRSF Income/yrMCD PortfolioMCD Income/yrGap
1← crossover$15,590$4,889.98$10,812$332.41+$4.8KIDRSF
2$23,806$7,124.73$11,819$488.02+$12.0KIDRSF
3$35,640$10,167.77$13,111$724.37+$22.5KIDRSF
4$52,361$14,226.41$14,832$1,091.05+$37.5KIDRSF
5$75,560$19,533.63$17,219$1,675.85+$58.3KIDRSF
6$107,194$26,344.00$20,688$2,641.85+$86.5KIDRSF
7$149,625$34,927.92$25,990$4,309.70+$123.6KIDRSF
8$205,663$45,564.28$34,590$7,351.77+$171.1KIDRSF
9$278,591$58,531.92$49,535$13,285.25+$229.1KIDRSF
10$372,193$74,100.38$77,746$25,833.37+$294.4KIDRSF

IDRSF vs MCD: Complete Analysis 2026

IDRSFStock

Idorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; license agreement with Mochida Pharmaceutical for the supply, co-development, and comarketing of daridorexant; and Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy. It also has a collaboration with Antares Pharma, Inc. for the development of a self- administered drug device product for Selatogrel; and Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase II clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.

Full IDRSF Calculator →

MCDConsumer Discretionary

McDonald's Corporation operates and franchises McDonald's restaurants in the United States and internationally. Its restaurants offer hamburgers and cheeseburgers, chicken sandwiches and nuggets, wraps, fries, salads, oatmeal, shakes, desserts, sundaes, soft serve cones, bakery items, soft drinks, coffee, and beverages and other beverages, as well as breakfast menu, including biscuit and bagel sandwiches, breakfast burritos, hotcakes, and other sandwiches. As of December 31, 2021, the company operated 40,031 restaurants. McDonald's Corporation was founded in 1940 and is headquartered in Chicago, Illinois.

Full MCD Calculator →
📬

Get this IDRSF vs MCD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

IDRSF vs SCHDIDRSF vs JEPIIDRSF vs OIDRSF vs KOIDRSF vs MAINIDRSF vs YUMIDRSF vs QSRIDRSF vs SBUX

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.